Novavax
NVAX
#5751
Rank
โ‚น100.87 B
Marketcap
โ‚น620.77
Share price
0.73%
Change (1 day)
-11.68%
Change (1 year)

Revenue for Novavax (NVAX)

Revenue in 2025 (TTM): โ‚น87.87 Billion

According to Novavax's latest financial reports the company's current revenue (TTM ) is โ‚น92.02 Billion. In 2024 the company made a revenue of โ‚น58.52 Billion an increase over the revenue in the year 2023 that were of โ‚น57.72 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Novavax from 1996 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น87.87 B50.16%
2024 โ‚น58.52 B1.37%
2023 โ‚น57.72 B-49.93%
2022 โ‚น115.30 B35.14%
2021 โ‚น85.31 B145.3%
2020 โ‚น34.78 B2513.63%
2019 โ‚น1.33 B-44.49%
2018 โ‚น2.39 B20.44%
2017 โ‚น1.99 B90.8%
2016 โ‚น1.04 B-56.69%
2015 โ‚น2.40 B23.98%
2014 โ‚น1.94 B50.39%
2013 โ‚น1.29 B6.89%
2012 โ‚น1.20 B55.56%
2011 โ‚น0.77 B4955.33%
2010 โ‚น15.36 M1.92%
2009 โ‚น15.08 M-70.51%
2008 โ‚น51.14 M-0.14%
2007 โ‚น51.21 M-75.31%
2006 โ‚น0.20 B-37.61%
2005 โ‚น0.33 B-13.98%
2004 โ‚น0.38 B-27.98%
2003 โ‚น0.53 B-21.22%
2002 โ‚น0.68 B-41.34%
2001 โ‚น1.16 B905.27%
2000 โ‚น0.11 B121.43%
1999 โ‚น52.16 M75.27%
1998 โ‚น29.76 M26.23%
1997 โ‚น23.57 M118.64%
1996 โ‚น10.78 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Agenus
AGEN
โ‚น9.59 B-89.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น216.83 B 135.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
โ‚น67.44 B-26.71%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
โ‚น53.88 B-41.44%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น5.221 T 5,574.64%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
โ‚น5.640 T 6,029.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น5.064 T 5,403.30%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚น3.804 T 4,034.68%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
โ‚น0.23 B-99.75%๐Ÿ‡บ๐Ÿ‡ธ USA